NTRA:NGS-Natera Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 110.2

Change

-0.59 (-0.53)%

Market Cap

USD 0.67B

Volume

0.81M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera Inc is a diagnostics company with proprietary molecular and bioinformatics technology that it is deploying to change the management of genetic disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-7.64 (-1.52%)

USD 41.65B
ICLR ICON PLC

-2.63 (-0.83%)

USD 26.38B
ILMN Illumina Inc

+0.15 (+0.14%)

USD 18.11B
MEDP Medpace Holdings Inc

-2.36 (-0.59%)

USD 12.38B
EXAS EXACT Sciences Corporation

+2.08 (+4.96%)

USD 7.74B
RDNT RadNet Inc

-1.05 (-1.80%)

USD 4.31B
GH Guardant Health Inc

-0.38 (-1.27%)

USD 3.66B
NEOG Neogen Corporation

-0.34 (-2.02%)

USD 3.63B
SHC Sotera Health Co

+0.24 (+2.12%)

USD 3.21B
OLK Olink Holding AB ADR

+0.01 (+0.04%)

USD 3.17B

ETFs Containing NTRA

GNOM:SW Global X Genomics & Biote.. 8.46 % 0.00 %

N/A

USD 6.38M
EKG First Trust Nasdaq Lux Di.. 5.03 % 0.00 %

-0.09 (0.51%)

USD 2.39M
CURG:LSE VanEck Genomics and Healt.. 4.87 % 0.00 %

+0.08 (+0.51%)

USD 6.90M
CURE:XETRA VanEck Genomics and Healt.. 4.82 % 0.00 %

+0.10 (+0.51%)

USD 6.98M
GN0M:XETRA Global X Genomics & Biote.. 4.57 % 0.00 %

-0.04 (0.51%)

USD 7.05M
GNOG:LSE Global X Genomics & Biote.. 4.50 % 0.00 %

+0.03 (+0.51%)

USD 6.81M
FCUS Pinnacle Focused Opportun.. 4.37 % 0.00 %

-0.44 (0.51%)

USD 0.03B
FRTY Alger Mid Cap 40 ETF 3.87 % 0.00 %

-0.35 (0.51%)

USD 0.04B
FBT First Trust NYSE Arca Bio.. 3.75 % 0.57 %

+1.11 (+0.51%)

USD 1.12B
ATFV Alger 35 ETF 3.48 % 0.00 %

-0.08 (0.51%)

USD 0.02B
PTH Invesco DWA Healthcare Mo.. 3.26 % 0.60 %

-0.17 (0.51%)

USD 0.14B
RJMG First Trust Exchange-Trad.. 3.15 % 0.00 %

-0.29 (0.51%)

USD 6.56M
CDNA:CA CI Bio-Revolution ETF 2.87 % 0.00 %

N/A

CAD 5.70M
BTEC Principal Healthcare Inno.. 2.81 % 0.42 %

+0.04 (+0.51%)

USD 0.02B
FXH First Trust Health Care A.. 2.73 % 0.63 %

+0.23 (+0.51%)

USD 1.23B
WBIO:LSE WisdomTree BioRevolution .. 2.56 % 0.00 %

+4.40 (+0.51%)

USD 3.00M
WDNA:LSE WisdomTree BioRevolution .. 2.56 % 0.00 %

-0.01 (0.51%)

USD 3.00M
FHH:CA First Trust AlphaDEX US H.. 2.53 % 0.77 %

+0.16 (+0.51%)

CAD 9.71M
FHH-F:CA First Trust AlphaDEX U.S... 2.53 % 0.00 %

N/A

CAD 0.01B
WRNA:XETRA WisdomTree BioRevolution .. 2.52 % 0.00 %

+0.02 (+0.51%)

USD 2.77M
WDNA 2.43 % 0.00 %

N/A

N/A
DOCG:LSE L&G Healthcare Breakthrou.. 2.26 % 0.00 %

+3.20 (+0.51%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 2.26 % 0.00 %

-0.01 (0.51%)

USD 0.07B
XMLH:XETRA L&G Healthcare Breakthrou.. 2.19 % 0.00 %

+0.02 (+0.51%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 2.19 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 2.19 % 0.00 %

+0.08 (+0.51%)

USD 0.07B
2B78:XETRA iShares Healthcare Innova.. 2.14 % 0.00 %

+0.03 (+0.51%)

USD 1.14B
2B78:F iShares Healthcare Innova.. 2.14 % 0.00 %

N/A

N/A
HEAL:SW iShares Healthcare Innova.. 2.06 % 0.00 %

-0.03 (0.51%)

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 1.93 % 0.00 %

-1.80 (0.51%)

USD 0.02B
W311:XETRA HAN-GINS Indxx Healthcare.. 1.88 % 0.00 %

-0.03 (0.51%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.88 % 0.00 %

-0.03 (0.51%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.88 % 0.00 %

-0.01 (0.51%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.88 % 0.00 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 1.61 % 0.39 %

+0.35 (+0.51%)

CAD 0.29B
CURE:AU ETFS S&P Biotech ETF 1.36 % 0.00 %

+0.34 (+0.51%)

USD 0.04B
XBI SPDR® S&P Biotech ETF 1.34 % 0.35 %

+0.19 (+0.51%)

USD 7.07B
FNY First Trust Mid Cap Growt.. 0.95 % 0.70 %

-0.32 (0.51%)

USD 0.32B
LABU Direxion Daily S&P Biotec.. 0.85 % 1.14 %

+0.82 (+0.51%)

USD 1.01B
JKK iShares Morningstar Small.. 0.64 % 0.30 %

N/A

USD 0.54B
ISCG iShares Morningstar Small.. 0.62 % 0.00 %

-0.23 (0.51%)

USD 0.55B
FNX First Trust Mid Cap Core .. 0.47 % 0.62 %

+0.13 (+0.51%)

USD 1.13B
SCHA Schwab U.S. Small-Cap ETF 0.36 % 0.05 %

-0.24 (0.51%)

USD 16.50B
IS0R:F iShares High Yield Corpor.. 0.34 % 0.00 %

N/A

USD 3.29B
JKJ iShares Morningstar Small.. 0.32 % 0.25 %

N/A

USD 0.21B
IUSN:F iShares MSCI World Small .. 0.17 % 0.00 %

-0.02 (0.51%)

USD 3.82B
IUSN:XETRA iShares MSCI World Small .. 0.17 % 0.00 %

+0.03 (+0.51%)

USD 3.82B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.02 (0.51%)

USD 0.09B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

-0.08 (0.51%)

USD 0.06B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+4.00 (+0.51%)

USD 1.06B
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.02 (+0.51%)

USD 1.06B
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

+0.04 (+0.51%)

USD 3.85B
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

+0.02 (+0.51%)

USD 3.85B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

-0.05 (0.51%)

USD 0.02B
IS0R:XETRA iShares High Yield Corpor.. 0.00 % 0.00 %

+0.04 (+0.51%)

USD 2.71B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

+12.00 (+0.51%)

USD 5.63M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

+0.07 (+0.51%)

USD 5.63M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 75.93% 98% N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.93% 98% N/A 94% A
Trailing 12 Months  
Capital Gain 119.30% 96% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 119.30% 96% N/A 96% N/A
Trailing 5 Years  
Capital Gain 345.07% 96% N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 345.07% 96% N/A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 45.43% 85% B 90% A-
Dividend Return 45.43% 85% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 87.56% 32% F 18% F
Risk Adjusted Return 51.88% 87% B+ 81% B-
Market Capitalization 0.67B 94% A 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 14.90 8% 8%
Price / Cash Flow Ratio -55.29 94% 95%
Price/Free Cash Flow Ratio -27.58 92% 91%
Management Effectiveness  
Return on Equity -50.59% 49% 32%
Return on Invested Capital -40.41% 51% 26%
Return on Assets -17.14% 49% 28%
Debt to Equity Ratio 36.97% 57% 47%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector